Clinical Trial

A Phase 2 Study to Investigate the Efficacy and Safety of Zelicapavir in Participants Aged ≥28 Days to ≤36 Months of Age Infected With Respiratory Syncytial Virus

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
Zelicapavir is a novel, orally administered, nonfusion replication inhibitor of RSV. It is being investigated in this Phase 2 study (EDP 938-203) as a potential treatment for RSV infection in both hospitalized and non-hospitalized children aged ≥28 days to ≤36 months who present with symptomatic RSV infection.
Protocol Amendment History 2 changes
critical Recruitment opened 2026-07-11
notable Trial sites expanded: 0 -> 8 locations 2026-07-11
Trial Details
NCT Number NCT07482657
Lead Sponsor Enanta Pharmaceuticals, Inc
Collaborators: PENTA Foundation, AMS-PHPT Research Collaboration, Chiang Mai University
Conditions RSV Infection, RSV, Respiratory Syncytial Virus (RSV)
Enrollment 150 participants
Start Date 2026-07-09
Primary Completion 2026-12 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2026-07-20